Analysis of fecal DNA methylation to detect gastrointestinal neoplasia.

Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology (2011) 1.86

Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74

Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60

Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev (2012) 1.57

Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24

DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun (2014) 1.12

Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res (2011) 1.10

Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer (2011) 1.03

Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol (2014) 1.02

Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88

Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol (2016) 0.87

MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol (2016) 0.87

An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87

The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer (2014) 0.86

Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World J Gastroenterol (2014) 0.84

MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res (2014) 0.84

Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol (2015) 0.84

Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol (2014) 0.82

Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract (2011) 0.82

RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics (2013) 0.82

Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives. World J Gastrointest Oncol (2015) 0.82

Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet (2014) 0.80

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire. World J Gastroenterol (2014) 0.80

Methylation of SFRP2 gene as a promising noninvasive biomarker using feces in colorectal cancer diagnosis: a systematic meta-analysis. Sci Rep (2016) 0.79

Incremental advances in excremental cancer detection tests. J Natl Cancer Inst (2009) 0.77

Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions. BMJ Open (2013) 0.76

Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. Virchows Arch (2016) 0.76

DNA methylation assay for colorectal carcinoma. Cancer Biol Med (2017) 0.75

Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) (2014) 0.75

DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics (2016) 0.75

Re: Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2010) 0.75

Improved amplification efficiency on stool samples by addition of spermidine and its use for non-invasive detection of colorectal cancer. BMC Biotechnol (2015) 0.75

The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.75

Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. Int J Mol Sci (2017) 0.75

Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. J Cancer Res Clin Oncol (2016) 0.75

TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker. Oncologist (2017) 0.75

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41

Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med (1993) 27.80

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet (1996) 20.53

Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet (1996) 18.89

Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04

The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med (2000) 13.19

Cancer epigenetics comes of age. Nat Genet (1999) 12.63

COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res (1997) 9.94

Gut flora in health and disease. Lancet (2003) 9.85

Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70

Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42

Anoikis mechanisms. Curr Opin Cell Biol (2001) 6.36

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38

MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22

Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80

Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst (2005) 3.73

Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science (1992) 3.58

The structural and mechanical complexity of cell-growth control. Nat Cell Biol (1999) 3.58

Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med (2002) 3.54

A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med (2007) 3.41

Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer (2005) 3.27

Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93

Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77

Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74

A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology (2005) 2.71

Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology (2000) 2.25

N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22

Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol (2006) 1.99

Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene (2007) 1.81

Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80

Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80

Stool screening for colorectal cancer: molecular approaches. Gastroenterology (2005) 1.61

Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res (2005) 1.59

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43

A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol (2008) 1.40

Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int (2000) 1.38

High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology (2008) 1.34

The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30

Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.27

RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer (2005) 1.19

Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci (2007) 1.19

Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer (2008) 1.15

A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev (2006) 1.14

SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02

Isolation of exfoliated colonic epithelial cells, a novel, non-invasive approach to the study of cellular markers. Int J Cancer (1992) 1.01

Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression. Virchows Arch (1998) 0.91

The secreted frizzled related protein 2 (SFRP2) gene is a target of the Pax2 transcription factor. J Biol Chem (2003) 0.88

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97

Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79

Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology (2004) 4.03

Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 3.83

Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res (2004) 3.54

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52

Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol (2008) 3.27

Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25

Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86

The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63

Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58

Lynch syndrome: form, function, proteins, and basketball. Gastroenterology (2005) 2.57

In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A (2009) 2.46

MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40

Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38

In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med (2006) 2.27

Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 2.27

Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24

Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol (2006) 2.21

A human beta-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol (2005) 2.12

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10

Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07

A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med (2004) 2.01

Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97

Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88

Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology (2007) 1.82

Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81

The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res (2013) 1.79

The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer (2007) 1.76

Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. Cell Cycle (2011) 1.76

Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74

Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol (2007) 1.73

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71

Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol (2002) 1.71

APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71

Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65

Intramuscular transplantation of engineered hepatic tissue constructs corrects acute and chronic liver failure in mice. J Hepatol (2009) 1.64

Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63

Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther (2009) 1.61

An assessment of the feasibility of sentinel lymph node-guided surgery for gastric cancer. Gastric Cancer (2004) 1.61

Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60

Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59

Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57

Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Clin Cancer Res (2005) 1.50

Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46

Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46

DS02 fluence spectra for neutrons and gamma rays at Hiroshima and Nagasaki with fluence-to-kerma coefficients and transmission factors for sample measurements. Radiat Environ Biophys (2007) 1.44

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43

Heat shock protein A4 controls cell migration and gastric ulcer healing. Dig Dis Sci (2015) 1.42

Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer (2005) 1.42

A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41

Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer (2011) 1.40

Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics (2011) 1.39

Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer (2011) 1.39

Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia (2009) 1.39

Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. Mutat Res (2006) 1.39

Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology (2006) 1.38

Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology (2012) 1.37

Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut (2013) 1.37

Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J Clin Invest (2012) 1.36

A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest (2009) 1.36

A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res (2012) 1.34

The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology (2008) 1.34

Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol (2003) 1.32

Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32

The outcome of living donor liver transplantation with prior spontaneous large portasystemic shunts. Transpl Int (2007) 1.32

Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res (2004) 1.32

High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther (2007) 1.30